Terms: = Lung cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
30 results:
1. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract] [Full Text] [Related]
2. Repotrectinib: First Approval.
Dhillon S
Drugs; 2024 Feb; 84(2):239-246. PubMed ID: 38279972
[TBL] [Abstract] [Full Text] [Related]
3. ETV6::ntrk3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
Gao L; Ai X; Lu S
Lung Cancer; 2024 Jan; 187():107443. PubMed ID: 38113652
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.
Shang X; Zhang W; Han W; Xia H; Liu N; Wang X; Liu Y
BMC Pulm Med; 2023 Nov; 23(1):482. PubMed ID: 38031067
[TBL] [Abstract] [Full Text] [Related]
5. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
6. NTRK fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract] [Full Text] [Related]
7. Congenital peribronchial myofibroblastic tumor (CPMT): a case report with long term follow-up and next-generation sequencing (NGS).
Zhou P; Li S; Wang W; Tang Y; Jiang L
BMC Pediatr; 2023 Apr; 23(1):184. PubMed ID: 37081446
[TBL] [Abstract] [Full Text] [Related]
8. Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.
Wang Z; Ge Y; Li H; Fei G; Wang S; Wei P
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36305643
[TBL] [Abstract] [Full Text] [Related]
9. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile.
Singh N; Singh R; Decker B; Robins D; Vidal G
BMJ Case Rep; 2022 Oct; 15(10):. PubMed ID: 36223973
[TBL] [Abstract] [Full Text] [Related]
11. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
Principe DR
Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
[TBL] [Abstract] [Full Text] [Related]
12. Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results.
Ni Y; Huang G; Yang X; Ye X; Li X; Feng Q; Li Y; Li W; Wang J; Han X; Meng M; Zou Z; Wei Z
Eur Radiol; 2022 Aug; 32(8):5616-5622. PubMed ID: 35226157
[TBL] [Abstract] [Full Text] [Related]
13. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract] [Full Text] [Related]
14. EGFR detection by liquid biopsy: ripe for clinical usage.
Batra U; Nathany S; Sharma M; Jain P; Dhanda S; Singh H; Jain A; Mehta A
Future Oncol; 2022 Jan; 18(1):85-92. PubMed ID: 34704813
[TBL] [Abstract] [Full Text] [Related]
15. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
17. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract] [Full Text] [Related]
18. Mammary analog secretory carcinoma of the thyroid gland: A rare cancer harboring TRK fusion.
Huang NS; Cao YM; Lu ZW; Guan Q; Chen JY; Ma B; Chen TZ; Bai QM; Wang YL; Ji QH
Oral Oncol; 2021 Apr; 115():105092. PubMed ID: 33189578
[TBL] [Abstract] [Full Text] [Related]
19. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
[TBL] [Abstract] [Full Text] [Related]
20. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
[Next]
